Find out if DURYSTA® is right for you.
Here are some things to think about before speaking to your eye doctor:
Is elevated eye pressure an issue?
Do you understand elevated eye pressure and the risks associated with it?
Do you have difficulty applying your eye drops every day? (Hard time using them, or forgetting?)
Ask your doctor about the DURYSTA®
Savings Program—eligible commercially-insured patients pay $0* for up to one implant per eye
*Offer valid only for commercially-insured patients with plans covering DURYSTA; patient out-of-pocket expense may vary. Offer not valid for patients receiving reimbursement from Medicare, Medicaid, or any other federal, state, or government-funded healthcare program. See Program Terms, Conditions, and Eligibility Criteria here or visit www.durystasavingsprogram.com. Program Terms, Conditions, and Eligibility Criteria: 1. This offer is valid only for commercially-insured patients 18 years of age or older whose insurance plans cover DURYSTA® (bimatoprost intracameral implant) 10 mcg. 2. This offer is not valid for use by patients receiving reimbursement under any federal, state, or government-funded healthcare programs (e.g., Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs); private indemnity or HMO insurance plans that reimburse patients for the entire cost of their prescription drugs; or where prohibited by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any federal, state, or government-funded healthcare program, patient will no longer be eligible for this offer and must call IQVIA Inc. at 1-833-DURYSTA, option 2, to stop program participation. This offer is not valid for cash-paying patients. This offer is also not valid for commercially-insured patients whose insurance plans do not cover DURYSTA. 3. Depending on insurance coverage, eligible commercially-insured patients pay $0 for each of up to one (1) DURYSTA implant per eye. This offer applies to the implant only and does not apply to costs for any other medication, procedure, or diagnostic service. Check with healthcare provider and insurance plan for discount. Patient out-of-pocket expense may vary. 4. Primary payer benefits must be applied prior to submitting a savings request on behalf of a patient. Patients may not seek reimbursement for value received from the DURYSTA Savings Program from any third-party payers. 5. Offer applies to implants administered during the current program period of July 1, 2022 through June 30, 2023. Savings requests, including the DURYSTA Savings Program Physician Reimbursement Request Form, the CMS-1500 claim form, and the Explanation of Benefits (EOB) from the primary payer, must be submitted online at AllerganEyeCue.com or by fax to 1-866-676-4069 within 180 days after the product is administered to the patient. 6. Allergan, an AbbVie company, reserves the right to rescind, revoke, or amend this offer without notice. 7. Offer good only in the USA, including Puerto Rico. Patients residing in or receiving treatment in certain states may not be eligible to participate in this program. 8. Void if prohibited by law, taxed, or restricted. 9. This offer is not transferable. The selling, purchasing, trading, or counterfeiting of this offer is prohibited by law. 10. This offer has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified prescription. 11. This offer is not health insurance. 12. Program expires June 30, 2023. 13. By redeeming this offer, patient represents they meet the eligibility criteria above and patient understands and agrees to comply with the terms and conditions of this offer. For questions about the program, please call 1-833-DURYSTA, option 2, or email [email protected]. Program managed by IQVIA Inc. on behalf of Allergan, an AbbVie company.
DURYSTA should not be used if:
DURYSTA may cause side effects involving the cornea, including increased risk of loss of cells from the inner layer of the cornea. You should not receive DURYSTA more than once in each eye. DURYSTA should be used with caution if you have a limited reserve of the cells lining the inner layer of the cornea.
DURYSTA should be used with caution if you have narrow or obstructed iridocorneal angles (the space where the iris, the colored part of the eye, and cornea meet).
DURYSTA may cause swelling of the macula, the center spot of the retina (back of the eye). DURYSTA should be used with caution if your eye does not have a lens, if you have an artificial lens and a torn posterior lens capsule, or if you have any risk factors for swelling of the macula.
DURYSTA may cause inflammation inside the eye or make existing inflammation worse.
DURYSTA may cause increased brown coloring of the iris, which may be permanent.
Eye injections have been associated with infections in the eye. It is important that you contact your doctor right away if you think you might be experiencing any side effects after an injection, including eye redness, sensitivity to light, eye pain, or a change in vision. Your doctor should monitor you following DURYSTA administration.
The most common side effect involving the eyes reported in patients using DURYSTA was eye redness. Other common side effects reported were feeling like something is in the eye, eye pain, being sensitive to light, a blood spot on the white of the eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.